Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Diseases 1

Interventions

Specimen Handling 625pembrolizumab 606Magnetic Resonance Spectroscopy 550Carboplatin 448Cisplatin 396Cyclophosphamide 394Biopsy 371Paclitaxel 323Nivolumab 322Gemcitabine 317Radiotherapy 283Bevacizumab 242Dexamethasone 222fludarabine 213Docetaxel 198durvalumab 194Oxaliplatin 187venetoclax 186atezolizumab 179Fluorouracil 176Rituximab 175Pemetrexed 172Capecitabine 167Radiation 164Doxorubicin 164Radiosurgery 159Ipilimumab 145Etoposide 142Leucovorin 140Lenalidomide 138

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × STX-478 × 90 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07174336 2026-06-04

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Eli Lilly and Company

Phase 3 Recruiting
920 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡